DCPH Deciphera Pharmaceuticals, Inc. Stock Quote

DCPH [NASD]

Index	-	P/E	-	EPS (ttm)	-4.90	Insider Own	27.70%	Shs Outstand	58.62M	Perf Week	7.49%
Market Cap	900.06M	Forward P/E	-	EPS next Y	-2.19	Insider Trans	8.51%	Shs Float	47.75M	Perf Month	24.88%
Income	-285.60M	PEG	-	EPS next Q	-0.66	Inst Own	68.00%	Short Float	14.06%	Perf Quarter	52.05%
Sales	100.20M	P/S	8.98	EPS this Y	-8.10%	Inst Trans	-4.63%	Short Ratio	5.40	Perf Half Y	28.00%
Book/sh	4.63	P/B	2.88	EPS next Y	17.70%	ROA	-62.10%	Target Price	10.78	Perf Year	-63.97%
Cash/sh	3.80	P/C	3.51	EPS next 5Y	21.00%	ROE	-81.40%	52W Range	6.51 - 38.91	Perf YTD	36.64%
Dividend	-	P/FCF	-	EPS past 5Y	-43.60%	ROI	-98.50%	52W High	-65.69%	Beta	1.14
Dividend %	-	Quick Ratio	3.50	Sales past 5Y	-	Gross Margin	96.90%	52W Low	105.07%	ATR	0.84
Employees	280	Current Ratio	3.70	Sales Q/Q	15.90%	Oper. Margin	-	RSI (14)	61.12	Volatility	6.63% 7.19%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	24.60%	Profit Margin	-	Rel Volume	0.77	Prev Close	13.73
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 04 BMO	Payout	-	Avg Volume	1.24M	Price	13.35
Recom	2.70	SMA20	12.79%	SMA50	20.79%	SMA200	-6.84%	Volume	951,706	Change	-2.77%

Feb-28-22

Downgrade

Barclays

Equal Weight → Underweight

$11 → $6

Nov-08-21

Downgrade

Stifel

Buy → Hold

$60 → $10

Nov-08-21

Downgrade

Canaccord Genuity

Buy → Hold

$72 → $12

Nov-08-21

Downgrade

Barclays

Overweight → Equal Weight

$50 → $11

Nov-05-21

Downgrade

Truist

Buy → Hold

$65 → $10

Sep-30-21

Resumed

Stifel

Buy

$60

Mar-31-21

Initiated

Credit Suisse

Outperform

$78

Feb-10-21

Upgrade

SVB Leerink

Mkt Perform → Outperform

$70

Dec-03-20

Initiated

Stifel

Buy

$75

Sep-14-20

Resumed

JP Morgan

Neutral

$52

May-07-20

Downgrade

Nomura

Buy → Neutral

$84 → $60

Mar-04-20

Initiated

Barclays

Overweight

$70

Dec-20-19

Reiterated

Jefferies

Buy

$53 → $77

Oct-29-19

Upgrade

SVB Leerink

Underperform → Mkt Perform

$29 → $34

Oct-22-19

Initiated

JMP Securities

Mkt Outperform

Oct-03-19

Initiated

H.C. Wainwright

Buy

$60

Sep-30-19

Initiated

Jefferies

Buy

$47

Jul-18-19

Initiated

Deutsche Bank

Buy

$42

Dec-31-18

Upgrade

B. Riley FBR

Neutral → Buy

$27 → $34

Sep-25-18

Initiated

Leerink Partners

Underperform

Jun-16-22 07:00AM	Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer Business Wire -6.02%
Jun-15-22 11:10AM	Deciphera (DCPH) Up More Than 30% in Past 3 Months: Here's Why Zacks +7.29%
Jun-03-22 11:31AM	Deciphera Pharmaceuticals, Inc. (DCPH) Up 4.3% Since Last Earnings Report: Can It Continue? Zacks
Jun-02-22 07:00AM	Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences Business Wire
May-11-22 02:43PM	We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully Simply Wall St. -5.91%
May-06-22 11:02AM	Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss Zacks -8.94%
11:01AM	Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y Zacks
10:37AM	Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked Zacks
May-05-22 11:30AM	Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics Zacks
May-04-22 02:21PM	Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss Zacks
08:25AM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results Business Wire
May-02-22 09:55AM	Can Deciphera Pharmaceuticals, Inc. (DCPH) Climb 79% to Reach the Level Wall Street Analysts Expect? Zacks +7.81%
08:00AM	Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022 Business Wire
Apr-29-22 04:05PM	Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares Business Wire -6.56%
03:12PM	AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates Zacks
02:25PM	Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates Zacks
Apr-28-22 02:35PM	BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates Zacks
11:12AM	Eli Lilly (LLY) Beats on Q1 Earnings, Ups Sales View, Stock Rises Zacks
Apr-27-22 08:45AM	NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:42AM	Deciphera Raises $150M Via Equity Offering Benzinga
12:02AM	Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants Business Wire
Apr-26-22 04:10PM	Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Business Wire -6.92%
03:01PM	Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Apr-22-22 12:08PM	4 Reasons to Add Deciphera (DCPH) Stock to Your Portfolio Zacks
07:39AM	The Zacks Analyst Blog Highlights Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals Zacks
Apr-15-22 09:55AM	Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 73%: Read This Before Placing a Bet Zacks
Apr-12-22 03:50PM	Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting Business Wire
Mar-10-22 11:30AM	Deciphera Pharmaceuticals, Inc. (DCPH) Down 15% Since Last Earnings Report: Can It Rebound? Zacks
Mar-09-22 07:00AM	Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference Business Wire +12.99%
Mar-03-22 04:19AM	Investors in Deciphera Pharmaceuticals (NASDAQ:DCPH) have unfortunately lost 82% over the last year Simply Wall St. -6.18%
Feb-09-22 12:01PM	Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues Beat Zacks +15.32%
Feb-08-22 05:15PM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM	Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results Business Wire
01:38PM	CIBC Asset Management Inc Buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, ... GuruFocus.com
Feb-07-22 09:53AM	Drug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPH Zacks
Feb-02-22 07:00AM	Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences Business Wire -6.58%
Feb-01-22 03:01PM	Analysts Estimate Deciphera Pharmaceuticals, Inc. (DCPH) to Report a Decline in Earnings: What to Look Out for Zacks
07:00AM	Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022 Business Wire
Jan-24-22 05:00PM	Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session Business Wire +5.35%
Jan-10-22 07:00AM	Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones Business Wire
Jan-03-22 07:00AM	Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire +13.72%
Dec-24-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com
Dec-21-21 08:44AM	Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Business Wire +5.09%
Dec-10-21 01:01PM	Here is What Hedge Funds Think About Deciphera Pharmaceuticals, Inc. (DCPH) Insider Monkey
Dec-09-21 12:09PM	Deciphera: Why There Wont Be a Quick Recovery InvestorPlace
Dec-08-21 07:38PM	Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ... GuruFocus.com
07:38PM	Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ... GuruFocus.com
Dec-03-21 07:24AM	The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma Zacks
Dec-02-21 11:31AM	Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 78.5% Since Last Earnings Report? Zacks
10:28AM	Biotech Stock Roundup: VRTX, AMGN's Pipeline Updates, BPMC's Acquisition & More Zacks
Dec-01-21 11:53AM	Deciphera (DCPH) to Prioritize Key Pipeline Drugs, Cut Jobs Zacks -7.30%
11:45AM	Deciphera Pharmaceuticals lays off more than a third of its staff American City Business Journals
Nov-30-21 06:11PM	Why Deciphera Pharmaceuticals Shot 12% Higher Today Motley Fool +12.08%
04:52PM	Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer And Losing Hard InvestorPlace
01:16PM	Dont Bet on a Deciphera Stock Comeback InvestorPlace
08:30AM	Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations Business Wire
Nov-29-21 11:40AM	Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why Zacks
Nov-24-21 10:07AM	The Petri Dish: $2.5M for another Bob Langer startup, Decibel extends Regeneron deal American City Business Journals
Nov-23-21 11:52AM	Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST Zacks
Nov-22-21 07:00AM	Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Business Wire
Nov-16-21 01:20PM	Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals InvestorPlace
Nov-08-21 07:24AM	10 Biggest Price Target Changes For Monday Benzinga +15.31%
Nov-05-21 12:35PM	Mid-Day Market Update: Gold Rises 1%; Deciphera Pharmaceuticals Shares Plummet Benzinga -75.50%
10:55AM	Deciphera Pharma Stock Plunges After Disappointing Trial Results Investing.com
08:40AM	Why Did Deciphera Stock Plunge 70% Today? Benzinga
07:00AM	Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study Business Wire
Nov-03-21 11:05AM	Deciphera (DCPH) Q3 Loss Wider Than Expected, Revenues Miss Zacks +5.78%
12:30AM	Deciphera Pharmaceuticals, inc (DCPH) Q3 2021 Earnings Call Transcript Motley Fool
Nov-02-21 05:15PM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM	Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results Business Wire
Oct-26-21 09:34AM	Deciphera Pharmaceuticals, Inc. (DCPH) Fell Out Of Favor With Hedge Funds? Insider Monkey
07:00AM	Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021 Business Wire
Oct-22-21 06:13AM	3 Biotech Stocks With Huge Catalysts Incoming Motley Fool
Oct-15-21 10:08AM	Deciphera (DCPH) Thrives on Qinlock, Overdependence a Woe Zacks
Oct-12-21 07:00AM	Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Business Wire +6.81%
Oct-07-21 09:00AM	Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Business Wire
Oct-06-21 08:34AM	Is the Options Market Predicting a Spike in Deciphera (DCPH) Stock? Zacks
Sep-17-21 10:57AM	Deciphera Presents New Data Across Pipeline At ESMO Congress Benzinga
08:17AM	Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor Business Wire
07:00AM	Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021 Business Wire
Sep-10-21 07:00AM	Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021 Business Wire
Sep-02-21 11:31AM	Deciphera Pharmaceuticals, Inc. (DCPH) Down 0.8% Since Last Earnings Report: Can It Rebound? Zacks
07:00AM	Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference Business Wire
Aug-18-21 08:19AM	Further weakness as Deciphera Pharmaceuticals (NASDAQ:DCPH) drops 5.1% this week, taking one-year losses to 37% Simply Wall St.
Aug-04-21 09:07AM	Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat Zacks +10.54%
08:01AM	Deciphera Pharmaceuticals, inc (DCPH) Q2 2021 Earnings Call Transcript Motley Fool
Aug-03-21 05:15PM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results Business Wire
Jul-29-21 05:31PM	15 Stocks that Will Double In 2021 Insider Monkey
Jul-27-21 03:02PM	Deciphera Pharmaceuticals, Inc. (DCPH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
07:00AM	Deciphera Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 3, 2021 Business Wire
06:13AM	2 Beaten-Down Biotech Stocks That Could Bounce Back Motley Fool
Jul-20-21 09:47AM	Hedge Funds Arent Crazy About Deciphera Pharmaceuticals, Inc. (DCPH) Anymore Insider Monkey
Jul-01-21 10:32AM	Deciphera (DCPH) Begins Dosing in Study on Cancer Candidate Zacks
Jun-30-21 04:01PM	Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene Business Wire
Jun-19-21 04:50AM	Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Jun-08-21 03:16PM	Top Biotech Stocks for Q3 2021 Investopedia
Jun-04-21 09:00AM	Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire
Jun-03-21 11:31AM	Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 10.8% Since Last Earnings Report? Zacks

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sherman Matthew L	EVP & Chief Medical Officer	Jun 16	Sale	10.75	1,768	19,006	76,884	Jun 21 04:37 PM
Martin Daniel C.	Chief Commercial Officer	Jun 16	Sale	10.75	1,311	14,093	49,521	Jun 21 04:35 PM
Pitman Jama	See Remarks	Jun 16	Sale	10.75	1,298	13,954	36,661	Jun 21 04:36 PM
Flynn Daniel Lee	Chief Scientific Officer	Jun 16	Sale	10.75	1,768	19,006	46,098	Jun 21 04:34 PM
Kelly Thomas Patrick	Chief Financial Officer	Jun 16	Sale	10.75	1,768	19,006	46,080	Jun 21 04:35 PM
Brightstar Associates LLC	10% Owner	Apr 29	Buy	10.00	1,478,978	14,789,780	18,051,348	Apr 29 04:31 PM
Kelly Thomas Patrick	Chief Financial Officer	Feb 16	Sale	9.05	1,368	12,380	47,848	Feb 18 05:01 PM
Sherman Matthew L	EVP & Chief Medical Officer	Feb 16	Sale	9.05	984	8,905	76,790	Feb 18 05:01 PM
Martin Daniel C.	Chief Commercial Officer	Feb 16	Sale	9.05	1,146	10,371	48,668	Feb 18 05:01 PM
Flynn Daniel Lee	Chief Scientific Officer	Feb 16	Sale	9.05	1,366	12,362	47,866	Feb 18 05:01 PM
Pitman Jama	See Remarks	Feb 16	Sale	9.05	1,146	10,371	37,959	Feb 18 05:00 PM
Sherman Matthew L	EVP & Chief Medical Officer	Oct 04	Sale	33.17	2,659	88,199	46,029	Oct 06 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience